Industry Session – Advancing Ambulatory Pathways for Relapsed/Refractory Multiple Myeloma – DEVELOPED AND FUNDED BY PFIZER LTD
| Monday, June 1, 2026 |
| 11:00 AM - 11:30 AM |
| Room 11B & C, Upper Level |
Details
Pfizer products are discussed – for prescribing information click here . . Adverse event reporting details are included at the start and end of the video. This promotional video is intended for UK healthcare professionals only.
On-demand session on ambulatory care pathways in Relapsed/Refractory Multiple Myeloma, featuring UK insights on innovative models, key operational considerations, and real-world approaches to improving access, capacity, and patient experience. PP-L1A-GBR-1343. May 2026
Speaker
Dr Kevin Boyd
Consultant Haematologist
The Royal Marsden
Speaker One
Kevin is a Consultant in Haematology at the Royal Marsden Hospital. Honorary Fellow Institute of Cancer Research London UK
Dr. Ceri Bygrave
Consultant Haematologist
UKMS
Speaker Two
Dr. Ceri Bygrave is Consultant Hematologist and the Clinical Lead for Myeloma at the University Hospital of Wales in Cardiff and Honorary Senior Research Fellow in Cardiff University, Dept of Cancer and Genetics.
Mr Grant Mehrjou
Myeloma Pharmacist
Cardiff and Vale University Health Board
Speaker Three
Grant Mehrjou is the Myeloma Pharmacist at Cardiff and Vale University Health Board, based at the University Hospital of Wales.
